Document is current

Article History

Received: 13 May 2023

Revised: 7 December 2024

Accepted: 7 January 2025

First Online: 5 February 2025

Competing interests

: CC reports personal fees as a speaker from Brystol Myers Squibb, outside the submitted work. DB reports personal fees as a speaker and/or in an advisory role from Accord Healthcare, Amgen, Sanofi, Servier, and Pierre Fabre, outside the submitted work. FS reports personal fees as a speaker and/or in an advisory role from Astra Zeneca, outside the submitted work. OB reports personal fees as a speaker and/or in an advisory role from Merck KGaA, Apmomia Therapeutics, Bayer, MSD, Amgen, Servier, and Pierre Fabre, outside the submitted work. All other authors have no conflict of interest.

: The database of this retrospective study was constituted in accordance with the reference methodology MR004 of the French National Commission on Informatics and Liberty (CNIL) and the Helsinki Declaration. According to current French regulations, no informed consent or additional ethical committee review was required for retrospective studies using data from medical records collected in daily practice by medical and nursing staff caring for the patient and without human involvement. Data were anonymized prior to statistical analysis. Based on the non-opposition principle, information on the purpose of the study and the type of data collected was given to each patient included in the study. Patients were free to decline to participate, but none refused. The present study was declared to the Health Data Hub under the number F20220624135714 and is available at .